Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE (GSK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

GlaxoSmithKline plc : GSK to acquire five million shares in Response Genetics for US$1.10 per share in cash

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/13/2012 | 02:29pm CEST

This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.

Issued: Thursday 13 September 2012, London, UK

GlaxoSmithKline plc (LSE: GSK) today announces that it has acquired five million newly issued shares of Response Genetics Inc. (RGI) (NASDAQ: RGDX) common stock at a purchase price of US$1.10 per share in cash. As a result, GSK now owns approximately 15.2% of the expanded share capital of RGI.

This transaction builds on the relationship GSK and RGI have been building over the years in the diagnostics field of oncology and vaccines. RGI performs companion diagnostic tests and other related activities for GSK's immunotherapies and oncology pipeline candidates.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com

GlaxoSmithKline Enquiries:

UK Media enquiries:

David Mawdsley

+44 (0) 20 8047 5502

(London)

Stephen Rea

+44 (0) 20 8047 5502

(London)

Sarah Spencer

+44 (0) 20 8047 5502

(London)

David Daley

+44 (0) 20 8047 5502

(London)

US Media enquiries:

Kevin Colgan

+1 919 483 2933

(North Carolina)

Melinda Stubbee

+1 919 483 2510

(North Carolina)

Sarah Alspach

+1 202 715 1048

(Washington, DC)

Jennifer Armstrong

+1 215 751 5664

(Philadelphia)

Analyst/Investor enquiries:

Sally Ferguson

+44 (0) 20 8047 5543

(London)

Tom Curry

+ 1 215 751 5419

(Philadelphia)

Gary Davies

+ 44 (0) 20 8047 5503

(London)

James Dodwell

+ 44 (0) 20 8047 2406

(London)

Jeff McLaughlin

+ 1 215 751 7002

(Philadelphia)

Ziba Shamsi

+ 44 (0) 20 8047 3289

(London)

GlaxoSmithKline cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk factors' in the 'Financial review & risk' section in the company's Annual Report 2011 included as exhibit 15.2 to the company's Annual Report on Form 20-F for 2011.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
05/25GLAXOSMITHKLINE : Studies Conducted at GlaxoSmithKline plc on Chronic Obstructiv..
AQ
05/25FINDINGS FROM GLAXOSMITHKLINE PLC YI : ...
AQ
05/25GLAXOSMITHKLINE : Studies from GlaxoSmithKline plc Provide New Data on Lupus (Qu..
AQ
05/25GLAXOSMITHKLINE : Researchers from GlaxoSmithKline plc Provide Details of New St..
AQ
05/25GLAXOSMITHKLINE : veteran Zhi Hong launches Brii Biosciences with $260M
AQ
05/24GLAXOSMITHKLINE : Chinese newco Brii launches with $260M
AQ
05/24GLAXOSMITHKLINE : EGX imposed LE10,000 fines on four listed companies
AQ
05/24GLAXOSMITHKLINE : GSK May Look at Merger Options for Indian Unit -The Economic T..
DJ
05/23Why the world needs more than one Ebola vaccine
RE
05/22ViiV Healthcare Receives EU Marketing Authorisation for Juluca (dolutegravir/..
AQ
More news
News from SeekingAlpha
05/25Eidos Therapeutics files for initial public offering 
05/25Kezar Life Sciences on deck for IPO 
05/24TOP WALL STREET HEALTHCARE GAINERS F : Allergan, CVS Health, Patterson, Sanofi, .. 
05/24GILEAD : Novartis's Kymriah Is Coming To America 
05/23High Rates And Inflation Could Pose A Systemic Risk To Biotech 
Financials ( GBP)
Sales 2018 29 826 M
EBIT 2018 8 109 M
Net income 2018 3 804 M
Debt 2018 18 280 M
Yield 2018 5,33%
P/E ratio 2018 19,32
P/E ratio 2019 16,26
EV / Sales 2018 3,11x
EV / Sales 2019 2,99x
Capitalization 74 390 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 15,5  GBP
Spread / Average Target 3,6%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Technology & Digital Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE13.42%98 990
JOHNSON & JOHNSON-11.45%325 801
PFIZER-0.91%208 713
NOVARTIS-8.30%194 397
ROCHE HOLDING LTD.-9.17%189 708
MERCK AND COMPANY5.01%158 970